…
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -5.57M | -7.18M | -8.59M | -8.97M | -45.72M |
| Net income | -5.06M | -7.18M | -8.59M | -8.97M | -45.72M |
| Selling general administrative | 18.02M | 11.99M | 10.45M | 10.22M | 16.86M |
| Selling and marketing expenses | - | 0.50M | 0.29M | - | 2.27M |
| Gross profit | -7.90M | 7.91M | 7.10M | 5.97M | 4.46M |
| Reconciled depreciation | 2.55M | 2.53M | 2.65M | 3.67M | 2.82M |
| Ebit | -14.43M | -7.16M | -8.09M | -10.24M | -21.49M |
| Ebitda | -11.83M | -4.63M | -5.44M | -4.93M | -18.67M |
| Depreciation and amortization | 2.60M | 2.53M | 2.65M | - | 2.82M |
| Operating income | -14.43M | -7.84M | -7.12M | -9.53M | -21.49M |
| Other operating expenses | 27.89M | 20.34M | 16.14M | - | 32.70M |
| Interest expense | 2.09M | 0.59M | 1.05M | 0.37M | 0.17M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.05M | 0.06M | 0.04M | 0.02M | - |
| Net interest income | -1.99M | -0.53M | -1.07M | -0.79M | -0.61M |
| Income tax expense | -0.51M | - | 0.00M | - | 0.19M |
| Total revenue | 13.47M | 12.50M | 11.13M | 10.54M | 11.63M |
| Total operating expenses | 6.52M | 15.75M | 14.22M | - | 25.53M |
| Cost of revenue | 21.37M | 4.59M | 4.03M | 4.56M | 7.17M |
| Total other income expense net | 8.86M | 0.66M | -1.47M | 1.35M | -24.04M |
| Net income from continuing ops | -4.95M | -7.18M | -8.59M | -8.97M | -45.72M |
| Net income applicable to common shares | - | - | - | -8.97M | -45.72M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 40.69M | 20.81M | 26.84M | 25.42M | 36.94M |
| Intangible assets | 13.47M | 8.18M | 9.67M | 10.89M | 12.53M |
| Other current assets | 0.52M | 2.94M | 0.72M | - | 1.05M |
| Total liab | 17.87M | 14.65M | 19.73M | 15.92M | 19.05M |
| Total stockholder equity | 22.83M | 6.16M | 7.11M | 9.50M | 17.89M |
| Deferred long term liab | - | - | - | 7.19M | 8.15M |
| Other current liab | 2.92M | 7.98M | 11.12M | 3.46M | 10.41M |
| Common stock | 122.95M | 103.96M | 98.23M | 92.47M | 92.14M |
| Capital stock | 123.13M | 103.96M | 98.23M | 92.47M | 92.14M |
| Retained earnings | -102.61M | -97.84M | -90.86M | -82.29M | -74.53M |
| Other assets | - | - | - | 7.19M | 8.15M |
| Cash | 15.41M | 1.96M | 6.48M | 3.02M | 7.98M |
| Total current liabilities | 13.00M | 8.71M | 12.62M | 8.17M | 12.83M |
| Current deferred revenue | 6.83M | - | 7.55M | - | 3.75M |
| Net debt | -9.48M | 5.03M | 1.58M | - | -0.78M |
| Short term debt | 1.06M | 1.04M | 0.95M | - | 0.97M |
| Short long term debt | - | - | - | 1.35M | - |
| Short long term debt total | 5.93M | 6.99M | 8.06M | - | 7.19M |
| Other stockholder equity | - | - | - | -0.68M | 0.28M |
| Property plant equipment | - | - | - | 8.56M | 10.97M |
| Total current assets | 19.78M | 6.46M | 9.56M | 5.96M | 13.44M |
| Net tangible assets | - | - | - | 5.80M | 13.50M |
| Net receivables | 2.22M | 1.04M | 1.57M | 1.49M | 1.89M |
| Inventory | 1.64M | 0.52M | 0.78M | 1.06M | 2.53M |
| Accounts payable | 2.18M | 1.37M | 0.55M | 1.14M | 1.45M |
| Accumulated other comprehensive income | 2.49M | 0.04M | -0.26M | - | 0.28M |
| Non currrent assets other | - | 0.00M | 0.02M | - | - |
| Non current assets total | 20.91M | 14.35M | 17.28M | 19.45M | 23.50M |
| Capital lease obligations | 5.94M | 6.99M | 8.06M | 8.44M | 7.19M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.05M | -0.10M | 4.31M | -4.36M |
| Change to liabilities | - | - | - | -6.18M | -3.10M |
| Total cashflows from investing activities | -2.59M | -0.05M | -0.10M | 4.31M | -4.36M |
| Net borrowings | 0.00M | - | -1.11M | 0.79M | -1.21M |
| Total cash from financing activities | 15.55M | 5.28M | 2.63M | 0.65M | -10.92M |
| Change to operating activities | - | - | - | 0.50M | 1.54M |
| Net income | -5.06M | -7.29M | -8.59M | -8.97M | -45.72M |
| Change in cash | 13.44M | -4.52M | 3.46M | -4.96M | -36.91M |
| Begin period cash flow | 1.96M | 6.48M | 3.02M | 7.98M | 44.89M |
| End period cash flow | 15.41M | 1.96M | 6.48M | 3.02M | 7.98M |
| Total cash from operating activities | 1.04M | -9.33M | 0.95M | -9.64M | -18.04M |
| Issuance of capital stock | 16.27M | 6.22M | 5.00M | - | 7.87M |
| Depreciation | 2.60M | 2.57M | 3.15M | 3.03M | 2.42M |
| Other cashflows from investing activities | - | - | -0.05M | - | - |
| Change to inventory | -1.04M | 0.26M | 0.28M | 0.81M | -1.35M |
| Change to account receivables | 1.17M | -0.37M | 0.81M | 0.93M | -0.18M |
| Other cashflows from financing activities | -1.07M | -0.95M | -1.26M | -0.13M | -18.79M |
| Change to netincome | - | - | - | -0.74M | 27.95M |
| Capital expenditures | 2.59M | 0.05M | 0.10M | 0.12M | 4.36M |
| Change in working capital | 4.60M | -1.47M | 0.05M | - | - |
| Stock based compensation | - | - | 0.45M | - | - |
| Other non cash items | -1.11M | -7.87M | 5.89M | - | - |
| Free cash flow | -1.56M | -9.39M | 0.85M | -9.79M | -4.36M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LDXHF Lumos Diagnostics Holdings Limited |
-0.01 20.00% |
0.04 | - | - | 5.01 | 2.89 | 4.90 | -0.22 |
| ABT Abbott Laboratories |
-0.03 0.03% |
109.93 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-3.04 2.90% |
101.80 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-9.21 2.75% |
325.87 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Samuel Lanyon | Exec. Chairman | NA |
| Mr. Douglas Ward | Chief Exec. Officer | NA |
| Mr. Barrie Lambert | Chief Financial Officer | NA |
| Dr. Sacha Dopheide Ph.D. | Chief Technology Officer | NA |
| Ms. Jennifer Christiansen | VP of Corp. Marketing & Communications | NA |
| Ms. Sarah Glubka | Sr. Director of HR | NA |
| Ms. Annie Bell | Sr. Director of Medical Affairs | NA |
| Ms. Sue Hibbeln | Sr. Director of Regulatory Affairs | NA |
| Mr. Paul Kase | Sr. VP of Commercial Operations | NA |
| Ms. Melanie Jaye Leydin B.Bus, C.A., CA | Company Sec. | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.